ALDX - Aldeyra Therapeutics, Inc.

QQQ $ 457.29 $ -11.41 (-2.42 %)

DIA $ 403.27 $ -5.26 (-1.29 %)

SPY $ 541.71 $ -7.80 (-1.42 %)

TLT $ 95.61 $ 0.50 (0.53 %)

GLD $ 225.83 $ -0.78 (-0.34 %)

Previous Close

$ 3.71

Open

$ 3.92

Bid

$ 3.69 x 100

Ask

$ 3.72 x 100

Day's Range

$ 3.67 - $ 3.92

52 Week Range

$ 1.42 - $ 8.38

Volume

261,517

Average Volume

Market Cap

220.43M

Beta (5Y Monthly)

$ 1.70

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-01-2024	06-30-2024	10-Q
2	05-02-2024	03-31-2024	10-Q
3	03-07-2024	12-31-2023	10-K
4	11-03-2023	09-30-2023	10-Q
5	08-03-2023	06-30-2023	10-Q
6	05-04-2023	03-31-2023	10-Q
7	03-09-2023	12-31-2022	10-K
8	11-10-2022	09-30-2022	10-Q
9	08-05-2022	06-30-2022	10-Q
10	05-05-2022	03-31-2022	10-Q
11	03-17-2022	12-31-2021	10-K
12	10-28-2021	09-30-2021	10-Q
13	08-05-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	03-11-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-06-2020	06-30-2020	10-Q
18	05-07-2020	03-31-2020	10-Q
19	03-12-2020	12-31-2019	10-K
20	11-07-2019	09-30-2019	10-Q
21	08-09-2019	06-30-2019	10-Q
22	05-10-2019	03-31-2019	10-Q
23	03-08-2019	12-31-2018	10-K
24	11-14-2018	09-30-2018	10-Q
25	08-09-2018	06-30-2018	10-Q
26	05-15-2018	03-31-2018	10-Q
27	03-29-2018	12-31-2017	10-K
28	11-09-2017	09-30-2017	10-Q
29	08-07-2017	06-30-2017	10-Q
30	05-15-2017	03-31-2017	10-Q
31	03-30-2017	12-31-2016	10-K
32	11-14-2016	09-30-2016	10-Q
33	08-10-2016	06-30-2016	10-Q
34	05-09-2016	03-31-2016	10-Q
35	03-30-2016	12-31-2015	10-K
36	11-13-2015	09-30-2015	10-Q
37	08-14-2015	06-30-2015	10-Q
38	05-14-2015	03-31-2015	10-Q
39	03-23-2015	12-31-2014	10-K
40	11-12-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Aldeyra Therapeutics Wraps Up Phase 3 Tria...
06/13/2024 11:04:23

Clinical Trial Results and Potential New Drug Application Resubmission Expected in the Second Half of 2024

Aldeyra Therapeutics Enrolls First Patient...
05/08/2024 11:14:47

Oppenheimer Reiterates Outperform on Aldey...
05/06/2024 11:46:39

Oppenheimer analyst Francois Brisebois reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Outperform and maintains $10 pri...

HC Wainwright & Co. Reiterates Buy on Alde...
05/06/2024 10:38:45

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 ...

Aldeyra Therapeutics Highlights Recent Pre...
04/25/2024 11:26:39

aldeyra-therapeutics-and-2-other-stocks-under-5-insiders-are-buying

Aldeyra Therapeutics And 2 Other Stocks Un...
04/04/2024 10:23:06

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confide...

Oppenheimer Upgrades Aldeyra Therapeutics ...
04/03/2024 13:58:41

Oppenheimer analyst Francois Brisebois upgrades Aldeyra Therapeutics (NASDAQ:ALDX) from Perform to Outperform and announces ...

HC Wainwright & Co. Reinstates Buy on Alde...
04/02/2024 12:43:21

HC Wainwright & Co. analyst Matthew Caufield reinstates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and announces $10 ...

Aldeyra Therapeutics Disclosed Clinical De...
03/28/2024 11:14:49

12-health-care-stocks-moving-in-tuesdays-after-market-session

12 Health Care Stocks Moving In Tuesday's ...
03/05/2024 21:31:07

Aldeyra Therapeutics Reports Advancement O...
01/04/2024 12:06:05

Based on positive biomarker results observed in adult cohort of Phase 2 clinical trial of ADX-629 in Sjögren-Larsson Syndrome, ...

On December 21, 2023, Aldeyra Therapeutics...
12/21/2023 21:19:12

As a result of the Exercise Period Extension, AbbVie may exercise the Option by delivering written notice to Aldeyra at any tim...

positive-news-for-skin-health-aldeyra-therapeutics-adx-629-achieves-key-milestones-in-atopic-dermatitis-study

Positive News For Skin Health: Aldeyra The...
12/19/2023 18:56:52

Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational R...

Market-Moving News for December 19th
12/19/2023 13:33:28

CGEN: 240% | Compugen Says It Will Be Eligible To Receive $10M Milestone Payment Upon Dosing Of First Patient In AstraZeneca Ph...

Aldeyra Therapeutics' Phase 2 Trial Of ADX...
12/19/2023 12:06:18

Aldeyra Therapeutics Schedules Conference ...
12/18/2023 21:03:28

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, Decem...

fda-rejects-aldeyra-therapeutics-dry-eye-disease-candidate-asks-for-additional-study

FDA Rejects Aldeyra Therapeutics' Dry Eye ...
11/28/2023 16:10:56

The FDA issued a complete response letter to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) New Drug Application (NDA) of reprox...

Aldeyra Therapeutics Shares To Resume Trad...
11/27/2023 21:13:28

Aldeyra Therapeutics Receives Complete Res...
11/27/2023 21:08:58

why-extreme-networks-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Why Extreme Networks Shares Are Trading Lo...
11/01/2023 17:59:52

Gainers

CLASS ACTION DEADLINES - JOIN NOW!

08/02/2024 Humana Inc. (HUM)

08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)

ALDXAldeyra Therapeutics, Inc.

Nasdaq aldeyra.com

$ 3.71 $ -0.23 (-5.84 %)

Thursday, 01-Aug-2024 15:59:48 EDT